Is Ginkgo stock a sell? Although possessing enough cash to keep it going for about two years at its current burn rate, I'm just not sure this company is going anywhere fast. To me, that makes Ginkgo stock a sell. Ginkgo Bioworks has become a penny stock -- and that's the least of its problems, Massaro is most concerned with management commentary that new "cell programs" -- of which the company expects to add 100 this year -- are no longer a great forecaster of revenue growth, and may give investors a false ...

Can this struggling stock turn things around? Ginkgo Bioworks (DNA -3.98%) is a cell programming company that claims to have large addressable markets (for bioengineered products) in multiple industries in which it can play a key role, and that those are worth trillions of dollars in total. But the problem is it may take more than a decade for those markets to reach that kind of size. Investors could require a lot of patience. While there may be a lot of potential for the business in the long run, investors ...

A few enterprising businesses are marketing themselves differently. As you may have heard, there's a new trend in biotech lingo wherein companies call themselves "TechBio" rather than "biotech" to emphasize their forward-thinking about the role of information technology. Biotechs like Ginkgo Bioworks (DNA 2.63%), Recursion Pharmaceuticals (RXRX 6.01%), and Schrödinger (SDGR 0.30%) could easily be described by the term, and some, like Recursion, even describe themselves that way. But what does this new term ...

BOSTON, May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. Further details, webcast links, and a replay of the presentations, fireside chats, and panels, if available, will be posted on the company's investor relations website at investors.ginkgobioworks.com. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for c ...

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy Ena Cratsenburg, Chief Business Officer, Ginkgo: "We're thrilled to join efforts with Sojitz and collaborate on bolstering the Japanese bioeconomy. Sojitz is a well respected trading company that has extensive relationships with many of the major industrial and chemical companies in Japan. We look forward to working with Japanese companies to leverage our synthetic biology platform to accele ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2024 Earnings Conference Call May 9, 2024 5:30 PM ET Company Participants Megan LeDuc – Manager-Investor Relations Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Mike Ryskin - Bank of America Steve Mah - TD Cowen Megan LeDuc Good evening, I’m Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I’m joined by Jason Kelly, our ...

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.09, delivering no surprise.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Ginkgo Bioworks, which belongs t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ______________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 ______________________ ...

Exhibit 99.1 Ginkgo Bioworks Reports First Quarter 2024 Financial Results Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 Conference Call Details Ginkgo will host a videoconference today, Thursday, May 9, 2024, beginning at 5:30 p.m. ET. The presentation will include an overview of first quarter fin ...

The stock market has been on an incredible run over the past year with tech and growth stocks surging. Traders have piled into many fast-moving companies in hopes of locking in quick trading gains.This excitement has increasingly moved back into the meme stock arena as well. While meme stocks somewhat fell out of fashion in 2022 and 2023, they are firmly back now. Traders gravitate to companies with high short interest, lots of trading volume, and the possibility for rapid price movements.With interest rate ...